rosiglitazone has been researched along with Hepatitis in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aryal, S; Candeloro, P; Decuzzi, P; Di Mascolo, D; Guindani, M; Hsueh, WA; J Lyon, C; Ramirez, MR; Wang, J | 1 |
| Liu, J; Pang, X; Wang, S; Wu, D; Zhang, X; Zhao, J | 1 |
| Baxter, JD; Collins, AR; Finegold, MJ; Gupte, AA; Hsueh, WA; Liu, JZ; Lyon, CJ; Minze, LJ; Moore, DD; Pratico, D; Ren, Y; Webb, P; Wiles, JR; Wong, ST | 1 |
| Dufour, JF; Oneta, CM | 1 |
| Kersten, S; Lichtenauer-Kaligis, E; Mandard, S; Müller, M; Richardson, TA; Stienstra, R; Tan, NS; Trautwein, C; Wahli, W | 1 |
| Bernhardt, C; Bruckert, E; Charlotte, F; Giral, P; Grimaldi, A; Hartemann-Heurtier, A; Jacqueminet, S; Lacorte, JM; Podevin, P; Poynard, T; Ratziu, V; Serfaty, L | 1 |
1 review(s) available for rosiglitazone and Hepatitis
| Article | Year |
|---|---|
[Alcoholic and non-alcoholic steatohepatitis].
Topics: Alcoholism; Biopsy; Cholagogues and Choleretics; Diagnosis, Differential; Fatty Liver; Fatty Liver, Alcoholic; Gemfibrozil; Hepatitis; Hepatitis, Alcoholic; Humans; Hypolipidemic Agents; Insulin Resistance; Liver; Liver Transplantation; Middle Aged; Obesity; Pilot Projects; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Ultrasonography; Ursodeoxycholic Acid; Weight Loss | 2004 |
1 trial(s) available for rosiglitazone and Hepatitis
| Article | Year |
|---|---|
Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.
Topics: Adiponectin; Adult; Aged; Alanine Transaminase; Fatty Liver; Female; Fibrosis; gamma-Glutamyltransferase; Hepatitis; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Necrosis; Placebos; Rosiglitazone; Thiazolidinediones | 2008 |
4 other study(ies) available for rosiglitazone and Hepatitis
| Article | Year |
|---|---|
Rosiglitazone-loaded nanospheres for modulating macrophage-specific inflammation in obesity.
Topics: Adipose Tissue, White; Animals; Anti-Inflammatory Agents; Bone Marrow Cells; Cell Line; Cells, Cultured; Gene Expression Regulation; Hepatitis; Hypoglycemic Agents; Inflammation; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardium; Nanospheres; Obesity; Polyvinyl Alcohol; Receptors, LDL; Rosiglitazone; Thiazolidinediones | 2013 |
Rosiglitazone attenuates angiotensin II-induced C-reactive protein expression in hepatocytes via inhibiting AT1/ROS/MAPK signal pathway.
Topics: Angiotensin II; Animals; C-Reactive Protein; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation; Hepatitis; Hepatocytes; Male; PPAR gamma; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2016 |
Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice.
Topics: Aging; Animals; Antioxidants; Dietary Fats; Fatty Liver; Gene Expression; Hepatitis; Liver; Male; Metabolic Syndrome; Mice; Mice, Knockout; Mitochondria, Liver; Oxidative Stress; PPAR gamma; Receptors, LDL; Rosiglitazone; Thiazolidinediones | 2010 |
The Interleukin-1 receptor antagonist is a direct target gene of PPARalpha in liver.
Topics: Animals; Anticholesteremic Agents; Carcinoma, Hepatocellular; Female; Gene Expression Regulation; Hepatitis; Hepatocytes; Humans; Hypoglycemic Agents; Interleukin 1 Receptor Antagonist Protein; Liver; Male; Mice; Mice, Knockout; PPAR alpha; Promoter Regions, Genetic; Pyrimidines; Receptors, Interleukin-1 Type I; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Tumor Cells, Cultured; Up-Regulation | 2007 |